Lower incidence of COVID-19 in high-altitude residents is intriguing, but requires more research

Despite recent reports of lower COVID-19 incidence among high-altitude populations, current data is insufficient to conclude that high altitude is protective against the SARS-CoV-2 virus, as reported in the peer-reviewed journal High Altitude Medicine & Biology.

"The reported lower incidence of COVID-19 among high-altitude residents is quite intriguing, but epidemiological observations presented so far from high-altitude regions are preliminary," state Matiram Pun, MBBS, MSc, University of Calgary, Erik Swenson, MD, University of Washington and Editor-in-Chief of High Altitude Medicine & Biology, and coauthors

The authors also conclude that there is currently little supporting evidence for any protective benefit of genetic or nongenomic adaptation to high-altitude hypoxia.

We should avoid reaching the conclusion that any community has an innate protection from COVID-19 in the absence of robust evidence."

Researchers

Sources:
Journal reference:

Pun, M., et al. (2020) Lower Incidence of COVID-19 at High Altitude: Facts and Confounders. High Altitude Medicine & Biology. doi.org/10.1089/ham.2020.0114.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Incidence and risk factors of an invasive fungal lung infection among COVID-19 patients